Parents
Sign in to add mentorGuido Kroemer | grad student | 2007 | University Paris 11 | |
(Mécanismes de dérégulation de l'apoptose au cours des syndromes myelodysplastiques : implication de la voie de signalisation de NF-kB) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Decaudin D, Dit Leitz EF, Nemati F, et al. (2023) Corrigendum to "Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma" [Eur J Cancer 126 (2020) 93-103]. European Journal of Cancer (Oxford, England : 1990) |
Abdul Razak AR, Bauer S, Suarez C, et al. (2021) Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
Decaudin D, Frisch Dit Leitz E, Nemati F, et al. (2020) Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma. European Journal of Cancer (Oxford, England : 1990). 126: 93-103 |
Fabre C, Mimura N, Bobb K, et al. (2019) Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 25: 2938 |
Grosjean-Raillard J, Adès L, Boehrer S, et al. (2015) Erratum to: Flt3 receptor inhibition reduces constitutive NFκB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. Apoptosis : An International Journal On Programmed Cell Death. 20: 1666-7 |
Fabre C, Gobbi M, Ezzili C, et al. (2014) Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients. Cancer Chemotherapy and Pharmacology. 74: 1057-64 |
Kaufman JL, Fabre C, Lonial S, et al. (2013) Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy. Clinical Lymphoma, Myeloma & Leukemia. 13: 370-6 |
Cormier F, Monjanel H, Fabre C, et al. (2013) Frequent engagement of RelB activation is critical for cell survival in multiple myeloma. Plos One. 8: e59127 |
Lawasut P, Chauhan D, Laubach J, et al. (2012) New proteasome inhibitors in myeloma. Current Hematologic Malignancy Reports. 7: 258-66 |
Fabre C, Mimura N, Bobb K, et al. (2012) Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4669-81 |